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On sexual transmission, HIV-1 infects 
CD4+CCR5+ T cells and remains localized in 
genital/rectal mucosa and draining lymph nodes 
for 10 d (1). Virus then spreads via the blood to 
other lymphoid tissue, especially that in the gut 
(2). There, it replicates profusely and the level of 
free virus in the blood rises exponentially to reach 
a peak, often millions of virus copies per milliliter 
of plasma, 21–28 d after infection. Virus level then 
falls, rapidly at first, until a stable level is reached 
(3, 4). This set point varies across patients and is 
partially predictive of the later course of disease in 
the absence of antiretroviral drugs; patients with 
low set points progress to AIDS more slowly (5).
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Identification of the transmitted/founder virus makes possible, for the first time, a ge-
nome-wide analysis of host immune responses against the infecting HIV-1 proteome.  
A complete dissection was made of the primary HIV-1–specific T cell response induced in 
three acutely infected patients. Cellular assays, together with new algorithms which iden-
tify sites of positive selection in the virus genome, showed that primary HIV-1–specific  
T cells rapidly select escape mutations concurrent with falling virus load in acute infection. 
Kinetic analysis and mathematical modeling of virus immune escape showed that the 
contribution of CD8 T cell–mediated killing of productively infected cells was earlier and 
much greater than previously recognized and that it contributed to the initial decline of 
plasma virus in acute infection. After virus escape, these first T cell responses often rapidly 
waned, leaving or being succeeded by T cell responses to epitopes which escaped more 
slowly or were invariant. These latter responses are likely to be important in maintaining 
the already established virus set point. In addition to mutations selected by T cells, there 
were other selected regions that accrued mutations more gradually but were not associated 
with a T cell response. These included clusters of mutations in envelope that were targeted 
by NAbs, a few isolated sites that reverted to the consensus sequence, and bystander muta-
tions in linkage with T cell–driven escape.
© 2009 Goonetilleke et al. This article is distributed under the terms of an 
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.jem.org/misc/terms.shtml). 
After six months it is available under a Creative Commons License (Attribution–
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).
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Figure 1. Identification of putative sites of positive selection using three independent tests. Subjects shown are CH40 (A), CH58 (B), and CH77 
(C). The horizontal axis indicates nucleotide positions aligned to HXB2 (nt 750–9750), and the vertical axis indicates significance from each of three tests. 
Tests for enriched mutations and clustered mutations (black and red bars, respectively) used sliding windows of 45 and 27 nt, respectively. Fixed-effects 
likelihood (FEL) test results from HYPHY are color coded to reflect the reading frame of the codon (+1, blue; +2, cyan; +3, green). Because overlapping 
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reading frames or recombination might influence FEL results, the FEL test was repeated for aligned fragments without regions where reading frames 
overlap and partitioned at potential recombination breakpoints (black x). Epitope locations for CTL (gray stripes) and NAb (black stripes) epitopes are jux-
taposed. For reference, a map of the HXB2 genome appears below. Methods are detailed in the text. Not shown are 10 (4 in CH40, 4 in CH58, 2 in CH77) 
regions that were identified as under selection by the first test but were predominantly the consequence of clusters of silent mutations, at least in the 
standard reading frames for HIV proteins. Some might represent cryptic epitopes, T cell response encoded in unconventional reading frames (63).
It is uncertain how the peak viremia of acute HIV-1 in-
fection is controlled. Some mathematical models (6–8) sug-
gest that the rampant early infection simply destroys so many 
CD4 T cells in the gut (2, 9) and elsewhere that the cell sub-
strate becomes limiting. However, reduction of peak viremia 
in rhesus macaques infected with simian immunodeficiency 
virus (SIV) was dependent on the presence of CD8 cells (10), 
either T or NK cells, or both. In HIV-1 infection, virus-spe-
cific CD8 T cells first appear in the blood just before the 
viremia peaks and then expand and contract as virus load 
falls (11–13). HIV-1–specific CD8 T cells are detectable be-
fore seroconversion and long before neutralizing antibodies 
(NAbs) (14). However, the mere presence of such T cells 
does not prove that they control virus. Indirect evidence for 
their importance comes from HLA class I allelic associations 
with low virus set point and with delayed progression to 
AIDS (15), but these effects, which are probably mediated by 
HLA class I–restricted T cells, could occur after the initial 
drop in viremia. Overall, this leaves the relative importance 
of CD8 T cells and the loss of infectable target cells to the 
decline of viremia of acute HIV-1 infection unresolved.
Further clues for a role of CD8 T cells in HIV-1 contain-
ment comes from studies demonstrating that they select virus 
escape mutations as early as 30–54 d after the peak viremia of 
acute infection (16, 17) and continue to select mutations 
throughout chronic infection (18–26). Nearly all these obser-
vations have been made after the steep decline from peak vi-
remia, as the virus is stabilizing at its set point, or later. Few 
studies have directly measured T cell escape; it is more often 
argued that changes in virus sequence in regions that corre-
spond to CD8 T cell epitopes matching the HLA type of the 
patient are selected by T cells (e.g., see reference 28). How-
ever, this approach can be confounded by the many overlap-
ping epitopes, that are presented by different HLA types (27). 
Approaches based on sequence alone also miss T cell responses 
to invariant epitopes as well as mutants selected by other im-
mune responses.
In this paper, a comprehensive study was made of the on-
togeny of the primary T cell response in acute HIV-1 infec-
tion. The single genome amplification (SGA) sequencing 
technique (28, 29) identified the single transmitted/founder 
virus sequence in each of four preseroconversion patients, be-
fore the immune response had made a discernable imprint on 
the virus quasispecies. The adaptive immune responses to the 
transmitted virus proteome were then followed using pep-
tides matched to autologous founder virus and to subsequent 
mutants, to capture responses that might otherwise be missed 
because of virus variability (30). This approach identified the 
first T cell responses in HIV-1–infected humans and showed 
that virus escape mutants were rapidly selected as viremia fell 
from its peak in acute infection. A mathematical model quan-
tified the downward pressure exerted by these CD8 T cell 
responses on the virus, showing that they contributed to the 
concurrent reduction of viremia. These data imply that vac-
cines that stimulate strong and broad early CD8 T cell re-
sponses to HIV-1 should be valuable.
RESULTS
Experimental strategy
A strategy was designed to detect the first T cell responses in-
duced by the single founder/transmitted virus in patients 
CH40, CH58, and CH77, each identified (31) in Fiebig stage 
II (3) (Table S1 and Fig. S1 show clinical details). Another 
untreated patient, SUMA0874, who was previously described 
(16, 21), was included after sequencing of his transmitted/
founder full-length viral genome (29). At the time of screen-
ing, there was no evidence of prior immune selection (29). 
Thereafter, patients were bled regularly, including at time 
points when virus load was falling from peak. T cell responses 
were initially measured by ELISpot and/or intracellular cyto-
kine staining (ICS) 6 mo after enrollment using peptides 
matched to the founder virus sequence. Earlier time points 
were also tested using peptides reactive at 6 mo and also pep-
tides spanning mutational clusters that were candidates for 
immune selection. The scale of the experiment and the lim-
ited number of PBMC available precluded peptide titrations, 
but at the 2 µg/ml (106 M) peptide concentration used in 
each experiment, there was either no recognition or clearly 
impaired recognition of the mutant peptide. This relatively 
high peptide concentration should have allowed the detec-
tion of even relatively low avidity T cell responses to the 
mutated epitope (32), so lack of response was convincing evi-
dence that these were true escape mutations.
Amino acid sequence changes from transmitted/ 
founder virus
Three distinct statistics were used to capture different aspects of 
positive selection and immune evasion for CH40, CH77, and 
CH58 (Fig. 1). The first used a sliding window of 45 bases to 
identify concentrated mutations, either highly mutated single 
sites or clusters of mutations, within the window. The second 
test identified clustered mutations in a 27-base sliding window. 
Finally, a tree-based statistic was used to identify single sites 
under positive selection (33, 34). When combined, 49 local-
ized regions were identified in the three patients where signifi-
cant variation emerged during the course of the study. The 
statistical significance of these regions of interest and a sum-
mary of all immunological responses identified are presented in 
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Fig. 2 provides details for these 49 sites of putative posi-
tive selection. Validated T cell epitopes are boxed and NAb 
epitopes are highlighted in blue. All sites are given a lower-
case letter to facilitate discussion. Distinct evolutionary tra-
jectories were seen in the 18 proven CD8 T cell epitopes. 
Table S2 and supported by the supplemental text. In the three 
patients, 22 variable regions were embedded in experimentally 
confirmed T cell or NAb epitopes. An additional 10 T cell epi-
topes were identified that were not under detectable selective 
pressure during the first 12–18 mo of infection.
Figure 2. Virus sequence changes emerge both early and rapidly at multiple sites across the HIV-1 proteome over the 12 mo after infec-
tion. Full-length SGA sequencing was performed at screening (0 d) for CH40, CH77, and CH58. Sequencing at multiple time points (indicated to the left 
of each block as days) subsequent to screening used SGA techniques but was derived from separate sequencing of the 5 (Gag and Pol) and 3 (Vif, Vpr, 
Tat, Rev, Vpu, Env, and Nef) regions of the virus genome. The sites in which significant variation was detected by 6 mo after infection are identified in 
columns including the percentage of SGA sequences that contained nonsynonymous (n.s.) changes at each time point. Some percentages are reported in 
either red or blue text. Red text indicates early and rapid escapes where n.s. changes occurred in at least 50% of SGA sequences by 50 d after screening. 
Blue text identifies those sites that were experimentally confirmed as containing Nab epitopes. Boxed columns identify T cell epitopes, with dotted boxes 
(red or black) indicating known or putative CTL motifs according to each patient’s HLA type (four digits), whereas solid boxes (red or black) identify those 
sites found in reactive peptides confirmed in T cell assays. Above solidly boxed columns, the reactive 18-mer peptide, relative to HXB2 standards, is shown 
and, if confirmed, the optimal CTL peptide. Below each column, n.s. substitutions are shown in parentheses; orange text indicates reversions to consensus 
clade B. * identifies those n.s. substitutions that were present in >50% of SGA sequences at the final visit. # denotes an insertion. The lower case letter 
preceding the protein (e.g., a. Gag) is a reference used throughout the paper and supplements to denote regions of positive selection. CH77.l and CH58.f 
identify regions of change in overlapping reading frames.
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supplemental text). Each was found in a variable loop in 
gp120 (V1 and V3 in CH40 and V2 in CH77; unpublished 
data). Overall, these complex patterns are signatures of im-
mune selection for CD8 T cell and NAb selected escapes.
12 regions of positive selection were identified within 
2–4 wk of screening (Fig. 2, red text; details about timing of 
responses and acquisition of variants can be found in Table S2 
and the supplemental text). Six sites were selected by de-
tectable T cell responses (Fig. 2, solid red boxes), four of 
which rapidly declined once the mutant virus became fixed 
(Figs. 4–7, CH40.t, CH77.s, CH77.cc, and CH58.e). At six 
other rapidly selected sites there were no detectable T cell 
responses (CH40.a, d, h, and i, CH58.g, and CH77.i). These 
mutations might be explained by mechanisms other than 
In 3/18 cases, the first variant in the epitope region simply 
replaced transmitted virus (Fig. 3 A, CH77.b; and Fig. S2). In 
a single case, five different variants of the peptide were ex-
plored, but the transmitted form remained dominant through-
out the study period (Fig. S2, CH40.q). In the remaining 
14/18 cases, multiple variants were explored with the final 
dominant form appearing later in the process (Fig. 3, B and C, 
CH77.cc, CH77.c; and Fig. S2). These included examples 
where mutations accrued not only within the defined epi-
tope but proximal to it as well; the nearby mutations might 
be compensatory or impact processing. NAb-driven escape 
mutations (CH40.k, CH40.l, CH77.o, and CH77.p) did 
not begin to accumulate until after 100 d into the infection 
and also had complex escape patterns (Fig. 2, blue text; and 
Figure 3. Examples of different patterns of escape. The alignment shows the transmitted form of the peptide that was susceptible to T cells with 
the variants that were observed over the course of the study underneath. Dashes indicate aa that are identical to the transmitted form and letters indi-
cate aa substitutions. The days from screening (left), the sequence (center), and occurrence of each variant and frequency (right) are shown. A plot of the 
frequencies of each form over time is shown above the alignment; the colors of the sequences correspond to those of the lines. The transmitted form is 
shown in black, the most common form at the last time point in red. The pattern shown in A, where a single variant completely replaced the transmitted 
form, was rare. The pattern in B was typical of rapid escape; the transmitted form was lost very quickly, but many mutated forms were rapidly explored by 
the virus, and the dominant form at the last time point was not among the earliest escape mutations. The pattern in C was typical of more gradual escape 
with continuing evolution, but this is a Gag epitope, where escape patterns tended to be of reduced complexity overall. Kinetic patterns of variation for 
all 19 peptides that stimulated T cell responses are shown in Fig. S2. All alignments and frequencies for all regions of interest are in the supplemental text.
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Figure 4. Early and rapid loss of the transmitted form and acquisition of ns mutations within the first weeks of HIV-1 infection result from 
T cell selection pressure. Within each panel, the HXB2 position sequence of both the wild-type and mutated peptides are given. The percentage of 
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founder virus, which is the proportion of SGA sequences produced which contain founder sequence spanning that relevant 18-mer peptide, is also given. 
The wild-type and mutated peptides, as well as HLA-matched known or predicted optimal epitopes, were tested in ex vivo IFN- ELISpot or ICS. CH40,  
A and B; CH77, C–E; CH58, F. ELISpot data are expressed as the mean spot forming units (SFU) per million PBMC (SFU/106) ± SEM and ICS data as percent-
age of CD8 memory T cells secreting IFN-, IL-2, MIP-1, TNF-, and/or CD107a.
direct escape from T cells. Two cases are candidates for early 
reversions, as the dominant early mutation in these regions 
restored the consensus amino acid (CH77.l and CH40.i). 
Four (CH40.a, h, and i and CH77.i; Table S2) covaried with 
other known early T cell escape mutations and could, there-
fore, be bystanders that were carried along with an escape 
mutation (discussed further in the next Results section). This 
left two sites, CH40.d and CH58.g, unexplained. CH40.d 
may be a processing mutation (discussed further in the next 
Results section). The site CH58.g was neither a good candi-
date for a reversion event nor a bystander mutation. There 
was no known or predicted T cell epitope in this site, but 
the rapid depletion of the transmitted form, with subsequent 
complex patterns of variation (detailed in supplemental text), 
is suggestive of immune escape.
There were 23 positively selected regions that arose more 
slowly (Fig. 2, black text) that were neither embedded in de-
monstrable T cell epitopes nor targeted by NAb. Most, how-
ever, were embedded either in a previously documented CD8 
T cell epitope or in a predicted epitope, based on anchor motifs 
given the patient’s HLA types (ELF software, Los Alamos Na-
tional Laboratory [LANL]), identified as dashed boxes in Fig. 2 
(details in Table S2). Eight regions (CH40.j, m, n, and s and 
CH77.t, u, w, and x) were only under positive selection pressure 
in the last sample, >1 yr after infection. These immune responses 
might not have been detectable at 6 mo when samples were 
screened using autologous peptide sets. 11 selected regions were 
in Env and might be attributable to undetected NAb escape. 
Four regions may demonstrate reversion to consensus sequence 
at later time points (CH40.r, CH58.a, CH77.f, and CH77.g; 
Table S2). Together with CH40.i and CH77.l, there are six can-
didates for reversion independent of immune escape; all were 
simple escapes involving only 1- or 2-aa mutations. Further sup-
port for a role for reversion in early selection is that mutations 
toward consensus were enriched in regions under positive selec-
tion that were not in experimentally defined epitopes (21/66), 
compared with selected sites that were in defined epitopes (8/58; 
P = 0.014 by a Fisher’s exact test). Reversions within epitopes 
recognized by T cells probably assisted escape (Fig. 2, CH40 
Gag 395–403 and CH77 Gag 240–249 and Nef 82–90). 
A handful of positions among the slower to evolve set were 
otherwise unexplained but covaried with a site in a selected 
epitope (Table S2). The mutational patterns within patients 
were highly interlinked, and some selected mutations may 
have carried along bystander mutations that would eventually 
be lost through recombination.
Evolution of T cell responses in early HIV-1 infection
Patient CH40. In patient CH40, a typical HIV-1–infected 
patient (set point, 13,183 cc/ml), escape in two epitopes was 
detected in the acute phase (Fig. 2; and Fig. 4, A and B). 
Several clustered residues in Nef 185–202 (Fig. 2, CH40.t), 
predominately an R192H change to the clade B consensus, 
were found in greater than half of the sequences 14 d after 
screening. The founder sequence was completely lost 29 d 
later when R192Q and S188R/N changes dominated. Both 
the transmitted and mutant forms of the 18-mer peptide (un-
published data) and a predicted HLA-A*3101-restricted no-
namer peptide, Nef 188–196 SLAFRHVAR, within it were 
made and tested for T cell recognition in ELISpot assays. This 
SLAFRHVAR epitope, which has not been previously de-
scribed, elicited a response, whereas mutant peptides were 
not recognized (Fig. 4 A). Another rapid change, R403K (an 
APOBEC-driven mutation, again toward the clade B consen-
sus) that occurred within the Gag peptide 389–406 (CH40.b) 
became fixed between 16 and 45 d after screening, as the virus 
load was falling. At 111 d from screening, another change, 
I401L (away from consensus), was observed with both changes 
persisting (though not occurring on the same virus molecule) 
at 1 yr from screening. The peptide that matched the founder 
virus sequence, but not its mutant, was recognized by T cells. 
From within the longer peptide, a predicted new HLA A*3101-
restricted epitope, Gag 395–404 CGKEGHIAR, was strongly 
recognized by T cells, whereas nonamers representing each of 
the mutants were not (Fig. 4 B).
Four other sites contained early and rapid mutations (Fig. 2, 
CH40, red text with and without dashed red box, and CH40.
a, d, h, and i) but were not detected in T cell assays at or 
around the time of complete loss of the transmitted virus se-
quence (not depicted). Between 16 and 45 d after screening, 
an A120D substitution in Gag 113–130 (CH40.a) moving 
away from consensus became fixed. An additional V128G 
substitution was detected from day 111, and by day 412 an 
insertion was observed at position 128. This region did not 
correspond to a known HLA-matched CD8+ T cell epitope, 
but a previous study described a possible CD4 T cell epitope 
at this site (35). Vpr 74–91 (CH40.i), which corresponded to 
an HLA-matched T cell motif, became fully mutated by day 
45 with complex changes including an initial S84R change to 
consensus persisting for the first year. Vif 161–178 (CH40.h) 
exhibited a single amino acid change, which had a high mu-
tual association with nucleotide position 8752 in the Nef epi-
tope region 186–202 (CH40.t) which was selected by T cells 
(see the third paragraph in the previous Results section), sug-
gesting that this was a mutation carried along by immune 
selection elsewhere. Lastly, a single Pol K76R change was 
observed in >50% SGA sequences in Pol (CH40.d) between 
days 16 and 45, with almost full loss of its transmitted form by 
day 412 (Fig. 2). This residue did not occur in a known HLA 
epitope but was proximal to the invariant T cell epitope Pol 
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Figure 5. T cell responses induced in acute HIV-1 infection in CH40. Ex vivo IFN- ELISpots were performed in CH40 over the first 12 mo of infec-
tion. (A) T cell responses that were both >50 SFU/106 and 4× background at one or more time points are shown. Data are expressed as the mean SFU/106 
PBMC ± SEM. Line color is used to group T cell responses that peaked at different times during the first year of HIV-1 infection. (B) Mapped T cell responses 
against the transmitted HIV-1 virus 181 d after screening for CH40. Each panel shows the T cell response to the 18-mer peptide (position relative to HXB2 
standards) described in the title. (C–K) Ex vivo IFN- ELISpots were performed on PBMC at the days indicated using peptides matching the transmitted vi-
rus. Data are graphed against percentage of transmitted virus, which reflects the proportion of SGA sequences produced at each time point that contain 
the transmitted virus sequence spanning that 18-mer peptide. The purple dotted line in H shows the percentage of transmitted virus in the proximal site 
CH40.d that may have had an impact on the processing of the Pol 80–97 epitope.
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80–97, which elicited a response in this patient. The Pol K76R 
change may therefore represent a mutation that alters pro-
cessing of Pol 80–97.
Fig. 5 A details the evolving pattern of T cell responses in 
CH40 over the first 12 mo of infection. The T cell responses 
to the first two epitopes described in the first paragraph of this 
section were present in the first PBMC sampled on day 16. 
The response to the Nef 185–202 (CH40.t) epitope decayed 
rapidly after the transmitted/founder form was lost (Fig. 5, 
A–C). The T cell response to the Gag 389–406 (CH40.b) 
peptide may already have been declining by day 16 but per-
sisted at a low level after the loss of the founder form (Fig. 5, 
A, B, and D). Three other T cell responses, which expanded 
after day 16, all selected escape mutants but more slowly: Vif 
113–130 (CH40.g), Rev 49–66 (CH40.o), and Env 830–847 
(CH40.q). The first two lost the founder form over 200 and 
400 d, respectively, and the third never fully replaced the 
transmitted with escape forms (Fig. 5, E–G). There were also 
four T cell responses (Gag 481–498, Pol 80–97, Pol 824–841, 
and Env 765–682), 40% of the whole response, that selected 
no escape (Fig. 5, H–K); although, as described in the previ-
ous paragraph, there is the possibility that the rapidly emerg-
ing K76R (CH40.d) mutation may have had an impact on the 
kinetics of the Pol 80–97 T cell response (Fig. 5 H). Overall, 
there were three phases of the T cell response in CH40: an 
early period of falling virus load and rapid escapes within 35 d 
of screening, then an increasing T cell response dominated by 
the Rev 49–66 (CH40.o)-specific response, and, lastly, a very 
strongly dominant response to an invariant Pol 824–841 epi-
tope (Fig. 5 A). The T cell responses were initially focused 
and then broadened over time.
Patient CH77. This patient was HLA B*5701 positive and 
controlled virus better than CH40, with viral load <2,000 cc/ml 
6 mo after screening, although a year later virus load increased 
to 9,165 cc/ml (Fig. S1). There were three early T cell re-
sponses that rapidly selected escape mutants in Env 350–368 
(CH77.s), Nef 17–34 (CH77.aa), and Nef 73–90 (CH77.cc). 
In each case, the T cells recognized the founder sequence but did 
not recognize the mutant peptides or recognized them poorly 
(Fig. 4, C–E). The T cell response to Nef 17–34 (CH77.aa) 
epitopes was no longer detectable by the ELISpot assay once 
the founder virus sequence was lost. Both responses to Env 
352–360 (CH77.s) and Nef 73–90 (CH77.cc) declined but 
remained detectable using ICS at 6 mo (Fig. 6, A–E).
Sequencing of single genomes meant that potential linkage 
between these escape mutations could be examined (Table I). 
The Env 352–360 (CH77.s) epitope QFRNKTIVF, which 
was a new epitope restricted by HLA Cw0401, escaped first 
between days 0 and 14. Changes were complex and included 
an APOBEC-driven mutation, R355K, which occurred 
within the optimal epitope and remained dominant over time. 
Next, the Nef 17–34 (CH77.aa) epitope mutated between 
days 0 and 32 and then the Nef epitope 73–90 (CH77.cc) mu-
tated between days 14 and 32. For the Nef 81–90 KAALDLSHF 
epitope restricted by HLA B*5701, two changes to clade B 
consensus, A83G and V76L, emerged at day 102 from screen-
ing, within and proximal to the epitope, with the A83G dom-
inant at the final visit. Thus, in 32 d, three complete escapes 
had been selected in rapid succession and accumulated on the 
same virus molecules.
A fourth very early sequence change was found in Tat in a 
highly variable region, 55–74 (CH77.l), spanning the nuclear 
localization signal and the C-terminal end of domain 1 (Fig. 2; 
and Table S2, CH77.l). Despite testing, both 14 and 21 d from 
screening, no T cell response was detected, including in the 
highly sensitive cultured ELISpot assay (unpublished data) (33). 
This seemed to be the fastest escape mutation in the three pa-
tients, and the complex pattern of escape strongly suggested im-
mune escape. However, the T to C change at nucleotide position 
5447, resulting in the I64T nonsynonymous change, was a re-
version to consensus in Tat. This region of the Tat gene overlaps 
part of Rev in another reading frame where the nucleotide 
change at position 5477 is synonymous. The nucleotides encod-
ing the putative Tat epitope actually fall within the region en-
coding a detected T cell epitope Rev 9–26 (CH77.l), which 
appeared to escape at a slower rate with amino acid changes in 
both reading frames. Thus, although an early T cell response 
against Tat might have been undetected in the earliest assays, an 
alternative explanation is that rapid reversion in Tat was the first 
mutation and subsequent immune escape in Rev generated the 
later changes in Tat.
The pattern of the predominant T cell responses in patient 
CH77 over the first 200 d is detailed in Fig. 6. After the three 
early escapes in Nef and Env, all of which occurred when virus 
load was falling toward set point, a strong immunodominant re-
sponse developed to the HLA B*5701-restricted Gag 240–249 
(CH77.c) TW10 epitope TSTLQEQVGW (Fig. 6, A–F). By 
6 mo (159 d) from screening, there were also strong responses 
to two epitopes in 334–351 (CH77.r) and overlapping peptides 
Env 597–614 and 605–622 (CH77.v), the latter of which also 
contained a B*5701-restricted epitope, TTTVPWNVSW. 
Both epitopes showed evidence of positive selection detectable 
at days 159 and 592, respectively (Fig. 2). Weaker responses to 
eight other epitopes (assuming unmapped responses to adjacent 
overlapping peptides were a single response), which included 
the HLA B*5701-restricted epitopes Gag 146–155 (CH77.b) 
IW9 ISPRTLNAW and Rev 9–18 (CH77.l) KTVRLIKRLY, 
were also detected at 6 mo (Fig. 6 B and Table S2). Although 
the breadth of the T cell response in CH77 was impressive, 
10/15 T cell epitopes were subject to virus escape over the first 
18 mo after infection, with escape from the HLA B*5701-
restricted TW10 epitope being one of the slowest. There were 
10 other sites of positive selection in the virus sequence that oc-
curred at a slower rate, for which no T cell response was found 
(Fig. 2). Six of these, two of which were in Env, had complex 
patterns of amino acid change, implying immune escape.
Patient CH58. This patient, who was also B*5701 positive, 
achieved very good control of virus load to 263 cc/ml (Fig. S1 
and Table S1). As with CH77, there was a very early escape 
within CH58.e, beginning just 9 d after screening (Fig. 2). 
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Figure 6. T cell responses induced in acute HIV-1 infection in CH77. (A) The kinetics of the T cell cytokine response to the three epitopes that un-
derwent early rapid escape and the B*5701 TW10 response that became immunodominant at 6 mo were described using ICS measuring total cytokine 
production in memory CD8 T cells. The dotted gray box highlights the first 50 d after screening when the virus load is declining to set point. Virus escapes 
that occurred in this period are denoted as both early and rapid. (B) Mapped T cell responses against the transmitted HIV-1 virus 159 d after screening for 
CH77 with overlapping peptides group with brackets with B*5701 epitopes highlighted in red. (C–F) Ex vivo IFN- ELISpots (C) or ICS (D–F) were performed 
on PBMC from patient CH77 at the days indicated using peptides matching the transmitted virus. Data from both patients are graphed against the per-
centage of wild-type virus, which reflects the proportion of SGA sequences produced at each time point that contain the transmitted virus sequence 
spanning that 18-mer peptide. Data are expressed as the mean SFU/106 PBMC. Error bars in C show SEM. ICS data represent the percentage of the back-
ground-subtracted IFN-, TNF-, MIP-1, IL-2, and CD107 production in memory CD8 T cells. Additional ELISpot data are shown as insets in D and E.
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Table I. CH77 3 SGA direct sequencing spanning CTL epitopes
Day SGA clone ENV 343-363 (CH77.s) NEF 17-35 (CH77.aa) NEF 75-94 (CH77.cc)
0 Consensus SHVVDKLREQFRNKTIVFNH RERRRRDEPAAVGVGPASQ PVRPMTYKAALDLSHFLKEK
14 CH77_WGA_B3a ...........K........ ................... ....................
14 CH77_WGA_C7 ...........K........ ................... ....................
14 CH77_WGA_C9 ...........K........ ................... ....................
14 CH77_WGA_C4 ...........K........ ................... ....................
14 CH77_WGA_D5 ...........K........ ................... ....................
14 CH77_WGA2b .................... ................... ....................
14 CH77E_L7 ...........S........ ......N............ ....................
14 CH77E_L8 ...........K........ .....K............. ....................
14 CH77E_M6 ..............A..... ....K.............. ....................
32 CH77_WK03_3_B1 ...........K........ ....G.............. .......Q............
32 CH77_WK03_3_D1 ...........K........ ........S.......... ............I.......
32 CH77_WK03_3_D2 ...........K........ ......E............ .......P............
32 CH77_WK03_3_D3 ...........K........ .....K............. .......Q............
32 CH77_WK03_3_TB1 ...........K........ .....K............. .......Q............
32 CH77_WK03_3_TB2 ...........K........ ......E............ .......T............
32 CH77_WK03_3_TB4 ...........K........ ........S.......... ..........H.........
32 CH77_WK03_3_TB5 ...........K........ ......N............ .......Q............
32 CH77_WK03_3_TB6 ...........K........ ..GA.ERR........... .......Q............
32 CH77_WK03_3_TB7 ...........K........ .....K............. .......Q............
32 CH77_WK03_3_TB8 ...........K........ ......E............ .......T............
32 CH77_WK03_3_TC1 ...........K........ ......N............ .......Q............
102 CH77_WK12_3_E1 .Y.........K........ ......N............ .L.....Q............
102 CH77_WK12_3_TA1 ...........K........ .....K............. .L.....Q............
102 CH77_WK12_3_TA2 ...........N........ .....T............. .L.....Q............
102 CH77_WK12_3_TB1 ...........K........ ....G.............. ........G...........
102 CH77_WK12_3_TB2 ...........K........ .....G............. ....I...G...........
159 CH77_WK24_3_TA1 ...........K........ K.....E............ .L......G........#..
159 CH77_WK24_3_TA2 ...N.......K........ .....G.........T... .L.....Q............
159 CH77_WK24_3_TA3 ...........K........ .....G....-------.. .L.....Q............
159 CH77_WK24_3_TA4 ...........K........ ......N........S... .L.....Q............
159 CH77_WK24_3_TA6 ...N.......K........ ......E............ .L......G...........
159 CH77_WK24_3_TB1 ...N.......K........ .....G............R .L.....Q.........#..
159 CH77_WK24_3_TB2 N..........K........ .....T............. .L.....Q............
159 CH77_WK24_3_TB3 ...N.......K........ .....K..........V.. .L.....Q............
159 CH77_WK24_3_TB4 ...........N........ .....K..........V.. .L.....Q............
159 CH77_WK24_3_TB5 G..........N........ .....T............R .L......G...........
159 CH77_WK24_3_TB6 ...N.......K........ ......E.........V.. .L......G...........
159 CH77_WK24_3_TB7 ...N.......K........ .....G............. .L......G...........
592 CH77_WK84_J1 .Y.........K........ ....GK............R ........G...........
592 CH77_WK84_G7 .Y.........K..A..... ....GK............R ........G...........
592 CH77_WK84_H12 ...A.......KD....... ....GK............R ........G...........
592 CH77_WK84_C9 .Y.........K........ ......E...........R .L......G...........
592 CH77_WK84_H3 .Y.........K........ .....G............R ........G...........
592 CH77_WK84_D10 .Y.........K........ ....GK............R ........G...........
Italics, nonsynonymous mutation occurring two or more times; underline, confirmed optimal T cell epitope; -, deletion; #, insertion; ., amino acids that are identical to the 
transmitted form.
aRepresentative of five further SGA clones (unpublished data).
bRepresentative of one further SGA clone (unpublished data).
1264 THE FIRST T CELL RESPONSES AFTER HIV-1 INFECTION | Goonetilleke et al.
Figure 7. T cell responses induced in acute HIV-1 infection in CH58. (A) The kinetics of the T cell cytokine response using ICS measuring the total 
IFN-, TNF-, MIP-1, IL-2, and CD107 T cell response in memory CD8 T cells. (B) Mapped T cell responses against the transmitted HIV-1 virus 145 d 
after screening for CH58. In C–G, each panel shows the T cell response, either by ICS or IFN- ELISpot, to the 18-mer peptide (position relative to HXB2 
standards) described in the title and is graphed against the percentage of wild-type virus, which reflects the proportion of SGA sequences produced at 
each time point that contain the transmitted virus sequence spanning that 18-mer peptide. The inset in E shows that the T cell response, as measured by 
ELISpot to a pool of mutant peptides (M), RRQDILDLWVYHTQGYFP, KRQEILDLWVYHTQGYFP, was half that of the response to the transmitted sequence 
peptide KRQDILDLWYHTQGYFP (T). The purple dotted line in F shows the percentage of transmitted virus in the proximal site CH58.h that may have im-
pacted on processing of the Nef 113–130 epitope. The inset in F shows the ELISpot response at day 70 to the optimal B*5701-restricted epitope HW10. In 
G, only three SGA sequences were produced at the indicated timepoint (+), so although some variation from the transmitted virus was detected, the 
changes were not significant in any of the three tests used (i.e., not listed in Fig. 2). Error bars in B, E, and F indicate SEM.
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because of failure to distinguish multiple variants. These muta-
tions first appeared 20 d after onset of symptoms (DFOSx), 
near peak viremia, and were consolidated by 34 d with 78% of 
sequences showing mutations (Fig. S3). There was a strong T 
cell response to the transmitted/founder sequence, with three 
of the variant peptides not recognized and weaker responses to 
the other two, collectively suggesting T cell selection pressure 
at this site. There was a brief increase of viremia between days 
25 and 50, shortly after this escape occurred (Fig. S3). The di-
rection comparison of sequencing strategies in this patient, il-
lustrates the power of the SGA approach in characterizing early 
virus selection.
Quantification of CD8 T cell escape in the four study sub-
jects summarized in Table II is based on a simple model (see 
Materials and methods), in which each epitope acts indepen-
dently and is under pressure by an independent CD8 T cell 
response. Fig. 8 shows how the model fitted the data from each 
patient. If there are no fitness costs associated with escape muta-
tions, then the rate of escape is the rate at which cells infected by 
founder viruses are depleted by CD8 T cells that target the epi-
tope under consideration, as the escape variant is not killed and, 
hence, its growth advantage is equal to the killing rate. If there 
are fitness costs associated with escape, then the rate of escape is 
lower. Hence, the rate of escape as shown is a lower bound on 
the CD8 T cell killing rate because of recognition of a single 
epitope. The median rate of escape observed in experimentally 
confirmed T cell epitopes was 0.14 d-1 and the maximum rate 
was 0.36 d-1. These estimates are substantially higher than prior 
estimates. For example, Asquith et al. (35) estimated a median 
rate of killing of HIV-1–infected cells by a single CD8 T cell 
response of 0.04 d-1 during primary infection, which is 3.5-fold 
lower than our estimate but based on previously published virus 
escapes that were later than those described here. Furthermore, 
the current estimate of the rate of death of productively infected 
cells based on the rate of viral decline during potent drug ther-
apy is  = 1 d-1 (36), suggesting that the CD8 T cell response to 
a single epitope could be responsible for, on average, 15% of 
this killing and, in some cases, could be responsible for as much 
as 35%. This implies that these CD8 T cells contribute substan-
tially to reduction of virus load by shortening the life span of 
HIV-1–infected cells that are replicating virus.
DISCUSSION
In this study, five findings were made that advance previous 
understanding of the role of T cell responses in acute HIV-1 
infection. The exact numbers of potential and actual T cell 
epitopes in the transmitted virus were determined. The kinet-
ics of virus escape, occurring as the virus load was declining 
from peak viremia, before set point, were shown to be earlier 
and faster than previously thought, extending previous obser-
vations on sequence change in acute infection (37). Some T 
cell responses to the transmitted form of the virus vanished af-
ter selecting early virus escape mutants. A small number of 
mutated sites were found that were not explained by escape 
from T cells, NAb, or reversion to consensus sequence; some 
of these were probably bystander mutations carried along with 
The T cell response to the Env 584–592 ERYLKDQQL epi-
tope spanning this site was initially recognized by a high pro-
portion (3.8%) of memory CD8 T cells (Fig. 7 A). Two 
codons within this epitope underwent selection, one away 
from consensus and the other involving multiple variants. At 
70 d from screening, a response was detected to the transmit-
ted peptide, but not the mutant peptide, in ELISpot (Fig. 4 F). 
This epitope could be restricted by either B*1402 or Cw*0701 
(Table S2). Escape from this T cell response preceded escape 
from the B*5701-restricted response to TW10 (CH58.c), 
which was subdominant 9 d after screening but expanded and 
became immunodominant by 6 mo (Fig. 7, A, B, and D). This 
TW10 epitope also underwent T242N and G248E changes 
that were found in most sequences 85 d from screening. Two 
nonsynonymous changes, K110R and D113E, occurred in 
Nef 105–122 (CH58.h) at a similar rate to that of escape from 
the TW10 T cell response. A T cell response was detected 
against the transmitted 18-mer at 70 d after screening (with 
50% loss in magnitude against mutated peptides) but not at day 
154 (Fig. 7 E). Another detected response in this patient re-
acted to the adjacent peptide Nef 113–130 and mapped to the 
HLA B*5701-restricted epitope 116–125 HTQGYFPDWQ. 
This T cell response declined rapidly (detectable in ELISpot 
but undetectable by ICS at day 154; Fig. 7, compare B and G) 
but no mutation occurred in this epitope. The two fixed non-
synonymous changes K110R and D113E, just described in 
CH58.h, were located upstream of this epitope and could be 
close enough to affect antigen presentation (34). It is possible, 
therefore, that these mutations shown in Fig. 7 F (dotted line) 
not only served as escape mutations against the Nef 105–122–
specific T cell response but could also have impacted on pro-
cessing of the adjacent HTQGYFPDWQ epitope. Finally, a 
T cell response was also made to the B*5701-restricted epi-
tope Gag 146–155 IW9, which was still strong at 6 mo and 
showed signs of mutation at around 1 yr (Fig. 7 G), although 
the number of SGA sequences at this visit was very low and 
the mutation was not significant (not a site of positive selec-
tion; listed in Fig. 2). There were three additional mutating 
regions, two of which were in Env. All had complex patterns 
of escape but none was in an HLA-matched epitope region 
and no T cell responses were detected (Fig. 2).
Noteworthy in this patient was the very early dominant 
but transient T cell response to the escaping epitope in Env, 
which was not HLA B*5701 restricted (with a possible second 
response to Env CH58.g which also mutated rapidly), fol-
lowed by strong responses by three HLA B*5701-restricted T 
cells where escapes were selected in the previously described 
order, TW10 before IW9 (24). These five T cell responses 
comprised the whole detectable response in this HLA B*5701 
patient who achieved excellent control of virus load.
Quantifying rates of CD8 T cell escape
For modeling, additional data were included from a fourth 
patient, SUMA0874, after identification of a cluster of mu-
tations in one short region in Rev by SGA sequencing, which 
was not previously detected by population sequencing 
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TW10 selected by T cells. There has also been some debate 
about the extent of amino acid sequence reversion to consen-
sus (assumed to be optimally fit virus) in early HIV-1 infection. 
Some have argued that such reversions of escaped sequences, 
originally selected in the patient’s sexual partner who has a dif-
ferent HLA type, can account for many of the early sequence 
changes (23, 26, 38–40). In this study, although six possible 
examples of reversion were identified, these represented a mi-
nority of all regions of mutation in early infection, which is in 
agreement with Liu et al. (17). Although in the accompanying 
paper Salazar et al. (29) found only random mutations in 
founder virus before peak viremia and no evidence of earlier 
selected mutations, we cannot exclude that some reversion to 
the most fit virus at the time of transmission occurred to ac-
count for the outgrowth of a single virus.
Another difficulty with the sequence-only approach is that 
it necessarily relies on the assumption that HIV-1 will eventu-
ally escape from all T cells and will leave an imprint on the vi-
rus. This assumption may be correct, but in the absence of 
data on the actual T cell responses and sequence information 
as to how virus has evolved from transmitted/founder virus, 
the contribution of those T cells that have not yet selected es-
cape mutations on virus load cannot be addressed. In this 
study, 34% (10/29) of epitopes that stimulated T cell responses 
immune escape mutations elsewhere. Finally, evidence is pro-
vided that the earliest CD8 T cell responses are causally linked 
to decline of virus load in acute infection.
The intensive strategy used in this paper can only be ap-
plied to small patient numbers, unlike previous methods which 
either incompletely sample the T cell response (11, 21) or rely 
on sequence changes alone (20, 24, 37). The latter approach, 
though elegant and applicable to large cohorts, makes assump-
tions as to whether the sequence has changed from consensus 
during earlier stages of infection and whether mutations are se-
lected by T cells. As found in this paper, mutations can be se-
lected by other immune responses, by mutual association, by 
selection in another reading frame, or by reversion to the con-
sensus form. Also, when sequencing is performed at later time 
points, the focus tends to be directed at well described epi-
topes, presented by more common HLA types, that escape rel-
atively slowly. T cell responses to the new epitopes that were 
found in this paper in the early immune responses may be 
missed, particularly when such early T cell responses vanish 
after the escape. For instance, it has been estimated that the 
Gag TW10 epitope, presented by HLA B*5701, was the most 
rapid to escape in a large HIV-1–infected cohort (24), but in 
CH58 and CH77 there were CD8 T cell responses that fully 
replaced the transmitted epitope well ahead of any escape in 
Table II. Higher escape rates are observed in the first T cells of HIV-1 infection
Patient Reference Mutation/sa Average rate 
escape, kb
t50c CD8 T cell 
epitoped
Confirmed T cell response 
(HXB2 position)e
day-1 days
CH40 a. Gag A120D 0.17 31 no no
CH40 b. Gag I401L, R403K 0.17 31 yes yes (Gag389-406)
CH40 d. Pol K76R 0.015 119 yes nof
CH40 h. Vif T167I 0.37 38 yes no
CH40 i. Vpr S84R 0.16 31 yes no
CH40 t. Nef S188R/N, R196Q 0.22 15 yes yes, (Nef185-202)
CH77 l. Tat I64TS 0.42 8 yes nog
CH77 s. Env R355K/S/N,T358A 0.36 9 yes yes, (Env350-368)
CH77 aa. Nef R21K/G, R22K/G/,TD23E/N, P25S 0.30 19 yes yes, (Nef17-34)
CH77 cc. Nef K82Q/T/P, A83G, L85H, L87I 0.29 24 yes yes, (Nef81-98)
CH77 b. Gag I147L 0.063 101 yes yes, (Gag140-157) IW9
CH77 c. Gag T242N,V247I, G248E/S 0.035 124 yes yes, (Gag236-253) TW10
CH58 e. Env Y586H 0.10 21 yes yes, (Env576-596)
CH58 g. Env F829V/S/L, I830M/L/F, A832T, V833I 0.12 27 no no
CH58 b. Gag I147L 0.007 430 yes yes, (Gag140-157) IW9
CH58 c. Gag T242N, G248E 0.085 60 yes yes, (Gag236-253), TW10
SUMA0874 Rev R48K, Q51H, Q53R, S54L, L55I 0.32 30 yes yes, (Rev47-55)
Median all demonstrated T cell epitopes  0.17 (max. 0.42)  0.14 (max. 0.36)
Summary of characteristics of several mutations that became fixed in the virus population within several weeks after the onset of symptoms.
aNote, that in the majority of cases, several different nonsynonymous mutations occurred in a given peptide in the model. All such escape variants are assumed not to be 
recognized by the corresponding CTL responses. Analysis of the extension of this model assumption will be presented elsewhere.
bThe rate of escape, k, determines the mean rate at which mutations accumulated in the viral population.
ct50 is the predicted time of the mutant to reach 50% frequency in the viral population.
dThe mutations occur in known CTL epitopes or in sites with CTL anchor binding motifs given the patient’s HLA type (ELF software, LANL).
eA CD8 T cell response (as measured by ELISpot or ICS) to a peptide corresponding to the transmitted virus was detected at that site.
fThis mutation is proximal to the Pol 80–97 epitope and may have had an impact on its processing. See also Fig. 5 H.
gThis region partially overlaps with Rev in another reading frame. See paragraph three of the CH77 section of the Results for further discussion.
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stimulation. It also implies either complete loss of the epitope, 
involving alteration in the amino acids which anchor the pep-
tide to the HLA molecule, or failure of T cell clones to recog-
nize the mutant epitopes. This finding also gives information 
on the half-life of specific CD8 T cells in HIV infection, which 
is short compared with previous estimates of longevity of HIV-
specific memory CD8 T cells in patients given antiretroviral 
therapy (43) but is consistent with the rapid turnover of all 
memory CD8 T cells in HIV-1–infected patients measured by 
McCune et al. (44). It is possible that this is a consequence of 
impaired CD4 T cell help, which has been shown in mice to be 
critical for the development of long-term T cell memory (45).
A key question is whether the earliest T cell responses con-
tribute to the early fall in viremia at the same time as they are 
selecting escape mutations. For complete escape to occur, all 
virus-infected cells that contribute to the viremia and express 
the original sequence must be replaced by cells infected by vi-
rus with the novel sequence. The new virus has the advantage 
that it is unlikely to be recognized by the selecting T cells. In 
CH77, such events were occurring in rapid succession (Table I). 
Therefore, it is likely that these CD8 T cells contribute to the 
reduction in virus load. A mathematical model was applied to 
the data, calculating the rates of virus escape and the contri-
bution of the T cell responses to the fall in virus load. The 
remained invariant over the first year after infection. They 
were mostly in the more conserved virus proteins, with six in 
Gag, three in Pol, and one in the Nef core. In CH40, there was 
an invariant Env epitope 765–682 in a coding region of gp41 
that is in an overlapping reading frame with Rev, so nonsyn-
onymous changes may be disadvantageous at this locus. The 
contribution to virus control by T cells specific for epitopes 
that did not mutate over the first year of infection might be 
important but is hard to assess. These T cells either could be 
functionally defective or, more consistent with the observation 
that invariant epitopes occurred in conserved regions of HIV-1, 
escape mutations might have too great a fitness cost for the vi-
rus (41, 42). In the patients studied in this paper, T cells specific 
for such epitopes became immunodominant once set point 
was established (Figs. 5–7). If vaccines could bring these re-
sponses forward, they might be effective in reducing peak vire-
mia to lower levels than are seen in natural infection.
The early sampling window in this study enabled detection 
of very early T cell responses that select rapid escapes and then 
disappear. The rapid decay of several T cell responses once the 
mutation was fixed was surprising. It suggests, particularly 
when there is no further selection on the epitope, that these 
escapes have little fitness cost to the virus because there is no 
tendency for the mutation to revert and maintain antigenic 
Figure 8. Mathematical modeling fitted to the he measured changes in the frequency of T cell escape mutations suggests that the first T 
cells induced by HIV-1 infection contribute to the control of acute viremia. Data shown is from patients CH40 (A), CH77 (B), CH58 (C), and SUMA0874 
(D). CH77.b and CH58.b mutations occurred within the IW9 Gag epitope. CH77.c and CH58.c mutations occurred within the Gag TW10 epitope.
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antibody, although in some cases this would imply an earlier 
antiviral effect of antibody than generally recognized, possi-
bly involving antibody-dependent cell cytotoxicity (48). NK 
cell recognition can be influenced by the peptides binding to 
the HLA class I molecules they recognize (49, 50), so this could 
account for some of the selected mutations, although this type 
of HIV-1 escape is yet to be demonstrated experimentally. 
However, an escape mutation in an HLA B27-bound peptide 
was found to increase binding to the ILT4 receptor found on 
monocytes (51). Future studies to explain putative immune es-
capes where no T cell response can be detected will be impor-
tant and could reveal other forms of immune protection.
Other causes of isolated selected mutations included some 
that were in mutual association (linkage) with a selected epi-
tope. The mutations could be carried along passively or incom-
plete mutual associations within the same proteins could 
represent attempts to compensate for mutations in the epitope. 
In one example, the mutation occurred on a different virus 
protein and so cannot compensate for an escape in the same 
protein but might affect virus RNA structure. Immune pres-
sure that targets codons found in overlapping reading frames 
may result in mutational clusters in more than one protein (the 
T to C change at position 5447 in CH77.l) or conversely limit 
virus escape because of fitness constraints imposed on the other 
open reading frame (see the Patient CH77 section of the Re-
sults for discussion of CH77.1).
Despite the limited numbers investigated, this study of-
fered the opportunity to observe the earliest T cell responses in 
two patients with HLA B*5701, both of whom initially con-
trolled the virus well. In both cases there were very rapid T cell 
responses selecting escape mutants while the acute viremia 
was falling. These preceded the establishment of the classical 
B*5701-restricted T cell responses to the TW10 and IW9 
epitopes, suggesting that these responses play more of a role 
in maintaining a low set point than in establishing it. The rel-
atively early appearance of these T cell responses to conserved 
epitopes, where escape has a known virus fitness penalty (41), 
may be the critical difference between these patients and CH40 
and SUMA0874, who did not control virus so well in early in-
fection. Ongoing studies will address this issue, which could be 
important for vaccine design.
Studies in the SIV challenge model in macaques have re-
ported findings similar to these (52, 53). However, there are 
differences between this experimental model and HIV-1 infec-
tion of humans that made it important to examine human in-
fection in this detail. The infection in rhesus macaques is 
artificial, and large inoculating virus doses have to be used to 
ensure infection. The challenge virus is more aggressive and 
the kinetics of infection and disease progression are faster than 
in humans (52, 54). Nevertheless, in Mamu A*01-positive an-
imals there was an early Tat-specific CD8 T cell response that 
selected escape mutations quickly while virus load was falling, 
and this was followed by a response to the stable Gag CM9 epi-
tope which escapes rarely and slowly (52). The findings were 
extended to other animals with different MHC types, with 
similar findings of early epitope escape mutations selected by 
contribution of experimentally confirmed T cells to killing of 
virus-infected cells in vivo, calculated from the rates of escape, 
was 3.5-fold higher than previous estimates made in later stages 
of infection (35). When compared with the current estimate of 
the death rate of virus-infected cells, it was found that a CD8 
T cell response to a single epitope could account for between 
15 and 35% of that killing. This implies that the earliest T cell 
responses are indeed helping to control the early viremia, even 
when the virus can escape. T cells specific for different epitopes 
may cooperate in suppressing virus and these effects should be 
additive to other causes of the falling viremia, including the 
loss of target cells for the virus.
The T cells that select rapid escape mutants must therefore 
be potent. The often observed pattern of multiple clustered 
mutations within and proximal to an epitope, which is com-
mon enough to be considered a signature of immune escapes, 
implies a real struggle between the virus and antiviral T cells. 
In this study, the first T cells can change the virus very rapidly, 
but this occurred at a time when there were very high levels 
of virus replication, reflecting very rapid turnover of infected 
cells. Later, as viral set point is reached, the virus turns over 
more slowly, possibly reflecting reservoirs in different cell pop-
ulations, the broadened T cell response, and the development 
of NAbs requiring multiple sequential/simultaneous changes 
for successful virus escape and replication. Thus, although the 
suppressive power of the T cell response in the first weeks of 
infection appears similar to that of a single antiretroviral drug 
(46), the comparison should best be made when the latter is 
given at the same stage of infection.
The virus SGA sequencing showed that there were several 
regions of change, frequently in Env, that were subject to posi-
tive selection but with no corresponding T cell response. It is 
possible that some responses were missed because of the timing 
of the cellular assays relative to the waning T cell response, that 
T cells might have been sequestered in sites other than the blood, 
or that they might not respond to peptide by releasing IFN-. 
However the assays used are sensitive and further attempts to re-
veal several of these T cell responses by culturing patients’ PBMC 
with peptides and IL-2, which greatly increases sensitivity, failed 
to detect low-frequency responses (33; not depicted). Neverthe-
less, some of these mutations were clustered like proven T cell 
and antibody-selected escapes and spanned regions with known 
or predicted HLA-appropriate potential epitopes (Table S2), 
suggesting undefined immune selection pressure.
It is possible that some mutations were selected by immune 
responses other than CD8 T cells, including CD4 T cells, anti-
body, and NK cells. CD4 T cells, restricted by class II HLA, also 
recognize peptides, and HIV escape by mutation in an epitope 
has been previously described (47). The epitopes recognized by 
CD4 T cells are less well characterized, but none were detected 
by ICS using peptides spanning regions of positive selection. 
Selection by NAb was seen in patients CH40 and CH77 in four 
sites that occurred in epitopes in the V1 and V3 region. Muta-
tions first appeared in these sites after day 100, which is consistent 
with previously described NAb kinetics in HIV-1 infection. It is 
possible that other Env mutations could have been selected by 
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counted, and then cryopreserved (107 cells/vial). Plasma was obtained after 
centrifugation of blood collected in EDTA tubes or from ficoll gradients of 
blood. Viral load set point was determined using an average of viral loads 
within a set point window (4). The criteria for defining the set point win-
dow for a given participant included removing outlying viral loads based on 
three major categories: values from the initial up- or downswing of viremia, 
values from the accelerating phase of the disease, and apparent outlying val-
ues during the set point interval.
Sequencing and alignments. RNA extraction, complementary DNA 
synthesis, and SGA was previously described by Salazar et al. (29). Peptides 
and substitutions are aligned relative to HXB2 standards (www.hiv.lanl.gov/
content/sequence/QUICK_ALIGN/QuickAlign.html).
HLA typing. HLA typing (Weatherall Institute of Molecular Medicine 
[WIMM], Oxford, England, UK) was performed using the sequence-specific 
primer method adapted from Bunce (56), which uses allele-specific primer 
combination in PCR amplification to provide absolute HLA resolution to two 
digits and high-probability resolution to four digits. CH40: A*0201/3101, 
B*4001/4402, and Cw*0302/0501; CH58: A*0101/2301, B*1402/5701, and 
Cw*0701/0802; and CH77: A*0205, B*5301/5701, and Cw*0401/1801.
Peptides. 18-mer peptides overlapping by 10 aa were synthesized (Sigma-
Aldrich; Medical Research Council Human Immunology Unit, WIMM, 
Oxford UK) to match the transmitted sequence of CH40, CH58, and 
CH77. Approximately 400 peptides for each patient (including >200 unique 
to that patient relative to consensus Clade A-D peptide sets) were arranged 
into pools in a matrix format using the Peptide Portal program (Statistical 
Center for HIV/AIDS Research and Prevention) adapting code from the 
Deconvolute this! program (57). Each peptide was repeated four times in the 
matrix peptide plate. LANL ELF software was used to identify HLA-matched 
known and predicted CTL epitopes (http://www.hiv.lanl.gov/content/
sequence/ELF/epitope_analyzer.html). Epitopes were predicted when the 
amino acid sequence contained anchor residues that match HLA motifs but 
occurred in epitopes not found on the LANL database. When such peptides 
gave a positive T cell response, it was considered likely that this identified 
both the optimal epitope and its HLA restriction.
Ex vivo ELISpot assays. Cryopreserved PBMCs were thawed and rested 
for 2 h before being placed in the ELISpot plates at 1 × 105 cells/well. Anti-
gens in the peptide plates were mixed 1:1 with PBMC in the ELISpot plate 
to a final concentration of 2 µg/ml and incubated for 20 h at 37°C in 5% 
CO2. Coating, development, and reading of ELISpot plates has been de-
scribed previously (33). A low threshold of positivity (30 SFU/106 PBMCs, 
>3× background) was applied to peptide pools to maximize sensitivity. Data
from positive pools were then deconvoluted (57) to identify candidate epi-
tope peptides. Putative positive peptide-specific T cell responses were con-
firmed in triplicate in a follow up IFN- ELISpot with 1 × 105 cells/well
and a peptide concentration of 2 µg/ml. A more stringent definition of posi-
tive responses was applied: ≥50 SFU/ million, >4× background. IFN-
ELISpot assays performed at other time points were performed similarly to
the deconvolution assays, although, in some cases, when cells were limiting,
0.5 × 104 cells/well were used against 9-mer peptides. For all assays, six neg-
ative control wells (media only) and at least 1 positive control well (10 µg/ml
PHA [Sigma-Aldrich]) were used.
Flow cytometry. Cryopreserved PBMCs were thawed and rested over-
night. PBMCs were stimulated with 2 µg/ml peptide with 1 mg/ml of anti-
CD28 mAb (L293; BD) and 1 mg/ml of anti-CD49d mAb (L25; BD) in the 
presence of anti-CD107a Alexa Fluor 680 (H4A3; BD), 5 µg/ml brefeldin A 
(Sigma-Aldrich), and 1 µg/ml of Golgi Stop (BD) for 5.5 h at 37°C in 5% 
CO2. After washing, the PBMCs were surface stained with anti–CD14–Cas-
cade blue (M5E2), anti–CD19–Cascade blue (HIB 19), anti–CD4-Cy5.5-
PE (M-T477), anti–CD8-QD705 (RPA-T8), anti–CD27-Cy5-PE (M-T271), 
T cells which recognized antigen with high functional avidity 
and later responses to more conserved epitopes (53). Thus, this 
model of infection mimics well the human responses observed 
in this study. The macaque studies, however, did not explore 
the full breadth of responses, and other T cells specific for epi-
topes that did not mutate may have been missed. Nor did these 
studies address the role of the early escaping T cell responses in 
controlling early viremia. The rhesus macaque model would 
provide an experimental opportunity to distinguish the relative 
roles in early virus control of the Mamu A*01-restricted Tat-
specific response versus other immune responses to more con-
served epitopes.
Overall, the findings reported in this paper show that the 
first CD8 T cells, despite limited breadth and very rapid virus 
escape, suppressed HIV-1 as virus load was declining from its 
peak. The influence of these T cell responses declined once 
the virus had escaped, but some control of virus was main-
tained by further waves of T cell responses, some of which 
did not select mutations or did so slowly. Many of these later 
T cells focused on more conserved regions of the virus and, 
if they were functionally competent, were likely to be impor-
tant in longer term suppression of the infection. It is prob-
able that the mutations that escaped slowly had a fitness cost 
for the virus, which could have been beneficial to the patient. 
Modeling implied that a single T cell response was contrib-
uting as much as 15–35% of viral decline with multiple T 
cell responses. The implication of these observations is that 
vaccine-induced HIV-1–specific T cells will contribute to 
control of acute viremia if they are activated early in subse-
quent HIV-1 infection. However, because of the very rapid 
escape that occurs within the first few weeks of infection, T 
cell vaccines will need to stimulate a considerable breadth of T 
cell responses, clearly greater than the median of three epitopes 
induced by the Merck vaccine (Corey, L. 2008. AIDS Vac-
cine 2008 Capetown. http://www.hivvaccineenterprise.org/ 
conference/archive/2008/Presentations/Tuesday/Special% 
20Session%2001/14h35%20L%20Corey.pdf). Supporting this 
view is the promising finding that a SIV Gag vaccine using 
two different adenovirus vectors in a prime-boost combination 
gave strong CD8 T cell responses to a mean of eight epitopes 
and gave substantial protection in macaques against SIVmac251 
challenge (55). In addition, attempts should be made to focus 
the earliest T cell responses on conserved epitopes that remain 
invariant or mutate with a fitness cost.
MATERiAlS AND METHoDS
Patients and samples. Patients 700010040 (CH40), 700010058 (CH58), 
and 700010077 (CH77) gave full informed consent to enroll in to the acute 
infection arm of the CHAVI 001 cohort. Human experiments were ap-
proved by the Prevention Sciences Review Committee Division of Ac-
quired Immunodeficiency Syndrome. In brief, acute infection was defined as 
positive for HIV-1 viral RNA in plasma but negative or discordant for HIV-1 
serology at a screening visit. Patients were bled at multiple time points, as 
indicated in Figs. 2–6, over 2 yr. Table S1 shows the demographical and 
clinical data of each patient. Patient SUMA0874 was detected in symptom-
atic acute HIV-1 infection as described by Jones et al. (21). Patient PBMCs 
were isolated from blood after centrifugation over ficoll. Cells were washed, 
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ulation were fitted by the following model: f(t)= f0/(f0 + (1  f0)e-kt), where 
f(t) is the frequency of the escape variant in the population and k is the rate of 
escape. The models assume that the escape variant is present at time t = 0 at 
the frequency f0. This equation is equivalent to the equation (2) in Asquith 
et al. (35). The rate at which an escape variant replaces the wild type is the rate 
of escape, and it is determined by the balance between the efficiency of the 
CTL clones evaded in killing the wild-type infected cells and the fitness cost 
of the mutations (35). The estimated rate of escape was robust to several 
changes in the model and the fitting procedure, such as including the genera-
tion of the escape mutant from the founder by mutation, transforming the 
frequency data using the arsin(sqrt) transformation, or by fitting the log-trans-
formed ratio of the frequency of the mutant to the founder. Because for the 
analyzed early escape variants there were rarely two consecutive time points 
in which both the wild type and the mutant were present, to estimate the es-
cape rates we replace the measured 0 and 100% frequency of the escape mu-
tant with 1/(n + 1) × 100% and n/(n+1) × 100%, respectively, where n is the 
number of viral sequences analyzed at these time points (35). The time at 
which the mutant is present at a frequency of 50% is t50 = [ln (1/f0 - 1]/k.
Online supplemental material. Table S1 provides demographical and 
clinical data for each study volunteer. Table S2 provides full details of each 
site of putative positive selection, giving significance for each statistical test 
applied and listing nonsynonymous changes to and from consensus within 
each site and whether a putative or validated T cell or antibody epitope cor-
responded to that region. The supplemental text provides additional detail of 
alignments and changes over time that support Table S2. Fig. S1 graphs viral 
load versus time for CH40, CH77, and CH58. Fig. S2 graphs variants versus 
transmitted founder sequence over time at each mutations cluster for dem-
onstrated T cell epitopes. Fig. S3 shows virus escape from the Rev (47–55) T 
cell response in acute infection in SUMA0874. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20090365/DC1.
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